期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

激肽释放酶-激肽系统的细胞内作用机制研究进展 被引量：8

Research progress on the intracellular mechanisms of kallikrein-kinin system
下载PDF
导出
摘要 激肽释放酶-激肽系统(kallikrein-kinin system,KKS)主要包括激肽释放酶、激肽原和激肽,激肽原在激肽释放酶的作用下转化为激肽和缓激肽,后者作用于缓激肽受体1(bradykinin 1 receptor,B1R)和/或受体2(B2R)或蛋白酶活化受体(protease activated receptors,PARs),调节细胞内丝裂原活化蛋白激酶(mitogen activated protein kinase,MAPK)、磷脂酰肌醇(-3)激酶(phosphatidylinositol 3-kinase,PI3K)/Akt/糖原合成酶激酶-3β(glycogen synthase kinase-3β,GSK-3β)、一氧化氮(nitric oxide,NO)、Janus激酶(Janus kinases,JAKs)/转录激活因子(signal transducer and activator of transcription,STATs)及线粒体内等多条信号通路而发挥生物学效应。文中旨在综述KKS调节细胞内信号通路的作用及其研究进展,以全面了解其作用机制。 Kallikrein-kinin system consists of kininogen , kallikrein, bradykinin and kinin .Kinins, derived from kininogen by tissue kallikrein , play their biological effects via bradykinin 1/2 receptors or protease activated receptors .Existing researches suggest that kinins exert various effects through different intracellular and mitochondrial signal pathways such as MAPK , PI3K/Akt/GSK3 be-ta, NO, JAKs/STATs.This review aims to elucidate the roles and the intracellular signal pathways of KKS in different diseases .
作者 石瑞峰 张仁良
机构地区 南京大学医学院附属金陵医院(南京军区南京总医院)神经内科
出处 《医学研究生学报》 CAS 北大核心 2015年第5期534-538,共5页 Journal of Medical Postgraduates
基金 国家自然科学基金(81070923 81100870) 江苏省自然科学基金(BK2011663 BK20141373)
关键词 缓激肽 组织型激肽释放酶 丝裂原活化蛋白激酶 糖原合成酶激酶-3Β 一氧化氮 Bradykinin Tissue kallikrein Mitogen activated protein kinase Glycogen synthase kinase-3β Nitric oxide
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献3

二级参考文献20

  • 1Xu G,Ma M,Liu X,et al.Is there a stroke belt in china and why? [J].Stroke,2013,44(7):1775-1783.
  • 2Borhani NO.Changes and geographic distribution of mortality from cerebrovascular disease[ J].Am J Public Health,1965,55:673-681.
  • 3Gaines K.Regional and ethnic differences in stroke in the southeastern United States population [ J ].Tenn Med,1997,90(7):280-283.
  • 4Howard G.Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes[J].Am J Med Sci,1999,317(3):160-167.
  • 5Towfighi A,Saver JL.Stroke declines from third to fourth leading cause of death in the United States:historical perspective and challenges ahead [J].Stroke,2011,42(8):2351-2355.
  • 6Centers for Disease Control and Prevention.CDC WONDER.Available at http://wonder.cdc.gov/.
  • 7Centers for Disease Control and Prevention.Ten great public health achievements-United States,1900-1999 [ J].MMWR Morb Mortal Wkly Rep,1999,48(12):241-243.
  • 8Howard V J,McClure LA,Meschia JF,et al.High prevalence of stroke symptoms among persons without a diagnosis of stroke or transient ische-mic attack in a general population:the REasons for Geographic And Racial Differences in Stroke(REGARDS)study [ J ].Arch Intern Med,2006,166(18):1952-1958.
  • 9He J,Klag MJ,Wu Z,et al.Stroke in the People's Republic of China.I.Geographic variations in incidence and risk factors [ J ].Stroke,1995,26(12):2222-2227.
  • 10Xue GB,Yu BX,Wang XZ,et al.Stroke in urban and rural areas of China[J].Chin Med J(Engl),1991,104(8):697-704.

共引文献20

同被引文献74

  • 1路英丽,邹冬辉,王忠山.人类组织激肽释放酶家族研究进展[J].国外医学（生理病理科学与临床分册）,2004,24(3):257-260. 被引量：1
  • 2陈向荣,游思维,金大地.BBB评分评估脊髓损伤大鼠后肢运动功能的探讨[J].中国脊柱脊髓杂志,2004,14(9):547-549. 被引量：53
  • 3戴勇,彭武建,李体远,杜珙,徐卓佳.导入人组织激肽释放酶基因治疗肾血管性高血压实验研究[J].中国分子心脏病学杂志,2005,5(2):452-456. 被引量：8
  • 4赵海苹,洪缨,谢俊大,解欣然,王晶,樊江波.小檗碱对肾性高血压心肌肥厚模型大鼠左心室重塑的影响[J].药学学报,2007,42(3):336-341. 被引量：28
  • 5Medvedev AE. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer[J]. J Interferon Cytokine Res, 2013, 33(9): 467-484.
  • 6Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity[J]. Nature, 1997, 388(6640): 394-397.
  • 7Temperley ND, Berlin S, Paton IR, et al. Evolution of the chicken Toll-like receptor gene family: a story of gene gain and gene loss[J]. BMC Genomics, 2008, 9: 62.
  • 8Barbalat R, Lau L, Locksley RM, et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands[J]. Nat Immunol, 2009, 10(11): 1200-1207.
  • 9Kang S, Lee SP, Kim KE, et al. Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages[J]. Blood, 2009, 113(11): 2605-2613.
  • 10Ren W, Wang Z, Hua F, et al. Plasminogen activator inhibitor-1 regulates LPS-induced TLR4/MD-2 pathway activation and inflammation in alveolar macrophages[J]. Inflammation, 2015, 38(1): 384-393.

引证文献8

二级引证文献69

医学研究生学报
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部